Cargando…
P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL
Autores principales: | Breccia, Massimo, Iurlo, Alessandra, Ferrara, Felicetto, Attolico, Immacolata, Malato, Alessandra, Bonifacio, Massimiliano, Rita Scortechini, Anna, Abruzzese, Elisabetta, Sanpaolo, Grazia, DI Renzo, Nicola, Lunghi, Monia, Impera, Stefana, Castagnetti, Fausto, Tiribelli, Mario, Santoro, Marco, Lunghi, Francesca, Maggi, Alessandro, Sargentini, Valeria, Piciocchi, Alfonso, Tringali, Claudia, Luciano, Luigiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428827/ http://dx.doi.org/10.1097/01.HS9.0000969556.89490.80 |
Ejemplares similares
-
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
por: Caocci, Giovanni, et al.
Publicado: (2020) -
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020) -
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019) -
P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
por: Breccia, Massimo, et al.
Publicado: (2023) -
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
por: Iurlo, Alessandra, et al.
Publicado: (2022)